Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Prepublished online as a Blood First Edition Paper on April 17, 2002; DOI 10.1182/blood-2002-01-0087.

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2002-01-0087v1
100/2/704    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moyo, V. M
Right arrow Articles by Brodsky, R. A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moyo, V. M
Right arrow Articles by Brodsky, R. A
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Submitted January 14, 2002
Accepted March 1, 2002

High-dose cyclophosphamide for refractory autoimmune hemolytic anemia

Victor M Moyo, B. D Smith, Isadore Brodsky, Pamela Crilley, Richard J Jones, and Robert A Brodsky*

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins, Baltimore, MD, USA
Medicine, MCP Hahnemann, Philadelphia, PA, USA

* Corresponding author; email: rbrodsky{at}jhmi.edu.

High-dose cyclophosphamide, without stem cell rescue, has been used successfully to treat aplastic anemia and other autoimmune disorders. To determine the safety and efficacy of high dose cyclophosphamide among patients with severe refractory autoimmune hemolytic anemia, we treated 9 patients with cyclophosphamide (50mg/kg/d for 4 days) who had failed a median of 3 (range; 1-7) other treatments. The median hemoglobin (HB) before treatment was 6.7 (range; 5-10) g/dl. The median time to reach an absolute neutrophil count (ANC) >= 500/µl was 16 (range; 12-18) days. Six patients achieved complete remission (normal untransfused hemoglobin for age and sex) and none have relapsed after a median follow up of 15 (range 4-29) months. Three patients achieved and continue in partial remission (HB >= 10 g/dl, without transfusion support). High-dose cyclophosphamide was well tolerated and induced durable remissions in patients with severe refractory autoimmune hemolytic anemia.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 JAMAHome page
M. Petri and R. Brodsky
High-Dose Cyclophosphamide and Stem Cell Transplantation for Refractory Systemic Lupus Erythematosus
JAMA, February 1, 2006; 295(5): 559 - 560.
[Full Text] [PDF]


click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020